A good response to furmonertinib fourth-line treatment of an advanced lung adenocarcinoma patient with EGFR exon20in and PIK3CA mutation: a case report and literature review DOI Creative Commons
Kai Sun, Peng Wang

Frontiers in Oncology, Год журнала: 2024, Номер 14

Опубликована: Дек. 17, 2024

Lung cancer, including small cell lung cancer (SCLC) and non-small (NSCLC), is the most prevalent globally remains leading cause of cancer-related mortality. Epidermal growth factor receptor (EGFR) mutations, frequently observed in female NSCLC patients, have revolutionized treatment strategies with advent tyrosine kinase inhibitors (TKIs). These therapies significantly improve survival are considered standard care for patients harboring EGFR mutations. However, eventually develop resistance to EGFR-TKIs, disease progression. Resistance mechanisms classified as either EGFR-dependent or EGFR-independent, latter involving bypass pathway activation, dysregulation downstream signaling cascades. EGFR-independent often renders all EGFR-TKIs ineffective, necessitating further investigation into mechanisms.

Язык: Английский

A good response to furmonertinib fourth-line treatment of an advanced lung adenocarcinoma patient with EGFR exon20in and PIK3CA mutation: a case report and literature review DOI Creative Commons
Kai Sun, Peng Wang

Frontiers in Oncology, Год журнала: 2024, Номер 14

Опубликована: Дек. 17, 2024

Lung cancer, including small cell lung cancer (SCLC) and non-small (NSCLC), is the most prevalent globally remains leading cause of cancer-related mortality. Epidermal growth factor receptor (EGFR) mutations, frequently observed in female NSCLC patients, have revolutionized treatment strategies with advent tyrosine kinase inhibitors (TKIs). These therapies significantly improve survival are considered standard care for patients harboring EGFR mutations. However, eventually develop resistance to EGFR-TKIs, disease progression. Resistance mechanisms classified as either EGFR-dependent or EGFR-independent, latter involving bypass pathway activation, dysregulation downstream signaling cascades. EGFR-independent often renders all EGFR-TKIs ineffective, necessitating further investigation into mechanisms.

Язык: Английский

Процитировано

0